adenosine - Profile

What are the generic drug sources for adenosine and what is the scope of freedom to operate?

Adenosine is the generic ingredient in three branded drugs marketed by Astellas, Am Regent, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hikma, Mylan Labs Ltd, Pharmobedient, Rising, Teva Pharms Usa, Wockhardt, Avet Lifesciences, Eugia Pharma, Hospira, Meitheal, and Mylan Asi, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are two tentative approvals for this compound.

Summary for adenosine

US Patents:	0
Tradenames:	3
Applicants:	16
NDAs:	23

Generic filers with tentative approvals for ADENOSINE

Applicant	Application No.	Strength	Dosage Form
		3MG/ML	INJECTABLE; INJECTION
		3MG/ML	INJECTABLE; INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ADENOSINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADENOSCAN	Injection	adenosine	3 mg/mL, 20 mL and 30 mL vials	020059	1	2005-04-18

US Patents and Regulatory Information for adenosine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	ADENOCARD	adenosine	INJECTABLE;INJECTION	019937-002	Oct 30, 1989		DISCN	Yes	No
Am Regent	ADENOSINE	adenosine	INJECTABLE;INJECTION	090010-001	Apr 28, 2009		DISCN	No	No
Fresenius Kabi Usa	ADENOSINE	adenosine	INJECTABLE;INJECTION	077133-001	Apr 27, 2005	AP	RX	No	No
Fresenius Kabi Usa	ADENOSINE	adenosine	INJECTABLE;INJECTION	205568-001	Apr 16, 2018	AP	RX	No	No
Gland	ADENOSINE	adenosine	INJECTABLE;INJECTION	206778-001	Feb 16, 2018	AP	RX	No	No
Gland Pharma Ltd	ADENOSINE	adenosine	INJECTABLE;INJECTION	077283-001	Jun 14, 2007	AP	RX	No	No

Expired US Patents for adenosine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995	5,731,296
Astellas	ADENOCARD	adenosine	INJECTABLE;INJECTION	019937-002	Oct 30, 1989	4,673,563
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-002	May 18, 1995	5,731,296
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995	5,070,877

Investment Scenario and Fundamentals Analysis for Adenosine

Last updated: February 20, 2026

What Is Adenosine?

Adenosine is an endogenous nucleoside that plays a critical role in various physiological processes, especially in regulating cardiac function. It is primarily used as an anti-arrhythmic agent (injectable form) to treat supraventricular tachycardia (SVT). In addition to its medical applications, adenosine serves as a biochemical tool in research and diagnostics.

Market Overview

Current Therapeutic Uses

• FDA-approved injectable use: Diagnosis and termination of SVT via intravenous administration.
• Research reagent: Used extensively in molecular biology and pharmacology.
• Potential future indications: Investigated for use in ischemia/stroke, cancer therapies, and neurodegenerative diseases.

Market Size and Growth

The global adenosine market was valued at approximately $100 million in 2022, expected to expand at a compound annual growth rate (CAGR) of 4.5% through 2030. The growth driven by:

• Increasing incidence of cardiac arrhythmias.
• Advancements in research exploring novel indications.
• Expansion of clinical trials assessing safety for off-label uses.

Competitive Landscape

• Manufacturers: Major pharmaceutical companies such as Par Pharmaceuticals, Fresenius, and generic drug producers.
• Pricing: Typical unit cost ranges from $25 to $50 per vial, with variations based on formulation and market region.
• Regulatory approvals: Approved in the US (FDA) and Europe (EMA) solely for the injectable formulation targeting SVT.

Pharmacological and Manufacturing Fundamentals

Molecular and Pharmacokinetic Profile

• Molecular weight: 267.24 g/mol.
• Mechanism of Action: Acts on adenosine A1 receptors in cardiac tissue, causing hyperpolarization and slowing conduction velocity in the AV node.
• Administration: Intravenous infusion; rapid onset (seconds) and short half-life (10 seconds).

Manufacturing Considerations

• Synthesis: Manufactured via chemical synthesis from adenine and ribose analogs.
• Stability: Stable when stored at -20°C; lyophilized form preferred for extended shelf life.
• Quality control: Stringent assay requirements for purity (>98%), endotoxin levels, and sterility.

Regulatory and Intellectual Property

• Patents around formulation and delivery methods have expired for many suppliers.
• No new patents on adenosine itself; focus has shifted to device delivery and combination therapies.
• Generic manufacturing pathways are well established.

Investment Opportunities and Risks

Opportunities

• Expansion into new indications: Clinical research could unlock additional therapeutic uses, increasing demand.
• Growing demand for cardiac diagnostics: As cardiac care improves, use of adenosine in diagnostic procedures may increase.
• Biotech innovations: Development of sustained-release formulations or targeted delivery systems.

Risks

• Limited patent protection: The absence of proprietary protections reduces pricing power.
• Regulatory challenges: Off-label uses require extensive clinical validation; regulatory hurdles could delay market expansion.
• Market saturation: Established competitors and generic products limit pricing and margins.

Financial Performance Expectations

• Small revenue base limits revenues; growth depends on clinical trial success for additional indications.
• Margins are generally high for pharmaceutical manufacturers, but profitability varies based on scale and region.
• Entry into the regenerative medicine market remains uncertain and highly competitive.

Regulatory and Policy Environment

• Approved in the US since 1990s for emergency arrhythmia therapy.
• Reimbursement policies largely coverage-based; new indications could face reimbursement hurdles.
• Regulatory pathway for additional indications involves phase II-III trials with FDA and EMA oversight.

Key Takeaways

Adenosine remains a niche pharmaceutical agent with stable demand driven primarily by cardiac diagnostics and emergency therapy. The market is mature but has potential for growth through research into new applications. Considerations for investment include the expiration of patents, the competitive landscape, and regulatory pathways for expansion. Monetization prospects hinge on successful clinical trials for off-label indications and development of innovative delivery systems.

FAQs

1. Is Adenosine a patented drug?
No. Patents on adenosine itself have expired; current patents focus on delivery systems or specific formulations.

2. What are the major risks for investors in adenosine?
Limited originator patent protections, potential regulatory delays, and market saturation with generics.

3. How quickly can adenosine affect cardiac function?
It acts within seconds after intravenous injection, with effects lasting less than a minute.

4. Are there any ongoing clinical trials for new indications?
Yes. Trials investigate adenosine’s role in ischemic stroke, cancer, and neurodegenerative conditions, but they are at early phases.

5. What factors influence adenosine pricing?
Manufacturing costs, formulation stability, regional regulatory environments, and competitive pricing.

---

References

[1] MarketsandMarkets. (2022). Adenosine Market by Application, Type, and Region – Global Forecast to 2030.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Products.
[3] European Medicines Agency. (2022). Summary of Product Characteristics for Adenosine.